华兰股份：子公司拟2000万元增资入股科迈生物

Core Viewpoint - Hualan Co., Ltd. announced a capital increase investment in Kema Biotechnology, acquiring a 9.53% stake post-transaction [1] Group 1: Investment Details - Hualan's wholly-owned subsidiary, Lingqing Zhizhi, plans to invest 20 million yuan in Kema Biotechnology's new registered capital [1] - Following the investment, Lingqing Zhizhi will secure a board seat and a preferential right to acquire Kema Biotechnology under equal conditions [1] Group 2: Company Background - Kema Biotechnology, established in 2021, focuses on antibody design using generative AI models and is incubated by the leading AI innovative drug development company, Jingtai Holdings [1]